HOME >> BIOLOGY >> NEWS
New study shows antibody-interleukin complexes stimulate immune responses

The findings could also be significant for developing new ways to help patients with autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, or juvenile diabetes.

The study, which was published in the February 16 issue of the online journal Science Express, showed that these injections caused a massive selective increase in the immune system's two main types of T cells.

"Our study shows that different cytokine-antibody complexes such as IL-2/IL-2 mAb could be clinically useful to selectively boost or inhibit the immune response in vivo," said Onur Boyman, a member of the Scripps Research Department of Immunology and lead author of the study.

The type of monoclonal antibody that was injected was specific to interleukin-2 (IL-2), a naturally occurring protein and a known immunotherapy for metastatic melanoma and renal cancer. The researchers showed that the anti-IL-2 monoclonal antibody (IL-2 mAb) expands the proliferation of specific T cells in vivo by increasing the biological activity of naturally occurring IL-2 through the formation of immune complexes. When combined with recombinant IL-2, some IL-2/IL-2 mAb complexes cause more than a 100-fold proliferation in CD8+ T cells, which can target virally infected cells or tumor cells.

Interleukin-2 increases the number of a subset of CD8+ T cells (referred to as antigen-experienced or memory T cells) in circulation and is often used for tumor immunotherapy and vaccination. However, IL-2 also stimulates CD4+ T regulatory cells, which can suppress those same memory T cells. Therefore, the prevailing view was that administration of IL-2 mAb removes the IL-2-dependent CD4+ T regulatory cells, which in turn leads to an expansion of CD8+ T cells.

"In the study, however, we noticed that the enhancing effect of IL-2 mAb correlated with naturally occurring levels of IL-2," Boyman said. "We concluded that, despite its reported neutralizing effect, IL-2 mAb actually expanded
'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
22-Feb-2006


Page: 1 2

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Clones on task serve greater good, evolutionary study shows
3. Pollution causes 40 percent of deaths worldwide, study finds
4. A study by the MUHC and McGill University opens a new door to understanding cancer
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Preclinical study links gene to brain aneurysm formation
7. In limiting life span, study finds booming bacteria innocent
8. Multicenter study nets new lung tumor-suppressor gene
9. MIT study: Maturity brings richer memories
10. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study
11. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... prescription digital therapeutics product portfolio with a near term focus on Type 2 ... and pharma commercialization experience across multiple therapeutic areas and classes. As Chief Commercial ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... the effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate ... reported that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming Comparability Issues ... An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, ... the most effective way to complete one? Will the study comply with all ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... HONG KONG (PRWEB) , ... July 09, 2020 ... ... chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in ... years, the PolyU research team led by Dr MA has been using the ...
(Date:7/7/2020)... , ... July 06, 2020 , ... ... Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts ... Bio-IT World has hosted an elite awards program, highlighting outstanding examples of how ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... today announced that the launch of a new clinical diagnostics immuno-oncology ... the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that aids ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... today announced the company has entered a license agreement with Roswell Park Comprehensive ... globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device ...
Breaking Biology Technology:
Cached News: